20:26 , Jul 20, 2018 |  BioCentury  |  Emerging Company Profile

Selective Regeneration

Surrozen Inc. is making tunable bispecific antibodies molecules it believes can overcome a major hurdle that has prevented other companies from tapping the Wnt pathway for regenerative medicine: namely, the inability to drug specific members...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ib/IIa data

LipimetiX Development LLC and Capstone reported pooled data from a double-blind, placebo-controlled, Australian Phase Ia trial and a double-blind, placebo-controlled, Australian Phase Ib/IIa trial in patients with refractory hypercholesterolemia and healthy volunteers with elevated fasting...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ib/IIa ongoing

LipimetiX Development LLC began the multiple ascending-dose portion of a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV AEM-28 in 15 patients with refractory hypercholesterolemia. Per protocol, the second portion began after the single ascending-dose...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ia started

LipimetiX Development LLC began a double-blind, placebo-controlled, Australian Phase Ia trial to evaluate single and multiple ascending-doses of IV AEM-28 in about 36 healthy volunteers with elevated cholesterol. LipimetiX Development is a JV between Capstone...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

TVC Imaging System: Clinical trial started

Infraredx began the international Lipid-Rich Plaque (LRP) study to evaluate the TVC Imaging System in about 9,000 patients presenting for coronary angiography in whom IVUS and/or NIRS evaluation is planned or could be used as...
07:00 , Jun 7, 2010 |  BioCentury  |  Emerging Company Profile

LipimetiX: Aping APOE

LipimetiX LLC is hoping to bypass defective LDL receptors in the livers of patients with heritable hyperlipidemia with its mimetics of apolipoprotein E , a protein that can target two additional hepatic receptors capable of...
07:00 , Oct 26, 2009 |  BioCentury  |  Product Development

Breaking through the BBB

The idea of using the brain's own transport receptors to ferry drugs across the blood-brain barrier has been around for more than a decade. AngioChem Inc. , one of a new generation of companies trying...
08:00 , Mar 2, 2009 |  BioCentury  |  Finance

Genentech rebuts Roche pessimism

Genentech rebuts Roche pessimism...
08:00 , Feb 16, 2009 |  BioCentury  |  Finance

Roche finds Genentech inflated

Roche finds Genentech inflated...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Company News

Lorus, Zoticon Bioventures. deal

The parties added Central America to the territories covered under Zoticon's license to Virulizin from Lorus' GeneSense Technologies Inc. subsidiary. Also, Lorus received a $150,000 milestone payment from Zoticon's Zor Pharmaceuticals LLC subsidiary, triggered by...